2型糖尿病肾脏保护的新药理学策略
本文综述2型糖尿病肾脏保护的新药理学策略。当前治疗依赖强化降糖和阻断肾素-血管紧张素-醛固酮系统的严格血压控制,但许多患者仍进展至终末期肾衰竭。临床试验显示钠-葡萄糖共转运体2抑制剂和靶向肠促胰素通路的药物可改善肾脏结局,内皮素受体阻断剂(如阿曲生坦)和非甾体盐皮质激素受体阻断剂(如非奈利酮)等新方法也在开发中。
要点
- SGLT2抑制剂和肠促胰素通路药物在临床试验中改善2型糖尿病肾脏结局
- 内皮素受体阻断剂和非甾体盐皮质激素受体阻断剂是新兴肾脏保护策略
- 现有强化降糖和RAAS阻断治疗下许多患者仍进展至终末期肾衰竭
核心结论
- 新一代降糖药物SGLT2抑制剂和肠促胰素通路药物,以及内皮素受体阻断剂和非甾体盐皮质激素受体阻断剂等新方法,为2型糖尿病肾脏保护提供了新策略。
研究设计与样本
- 本文为综述,概述近期与2型糖尿病肾脏疾病管理新治疗策略相关的临床数据。
主要发现
- 临床试验显示SGLT2抑制剂和靶向肠促胰素通路的药物可改善2型糖尿病患者的肾脏结局。
- 基于对糖尿病肾脏损伤机制的理解,开发了阻断内皮素受体(如阿曲生坦)和非甾体盐皮质激素受体(如非奈利酮)的药物。
临床怎么用
- 在现有强化降糖和RAAS阻断基础上,可考虑具有肾脏获益证据的新一代降糖药物及新兴肾脏保护药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Type 2 diabetes is the leading cause of impaired kidney function, albuminuria, and renal replacement therapy globally, thus placing a large burden on health-care systems. Current treatment strategies rely on intensive glucose lowering as well as strict blood pressure control through blockade of the renin-angiotensin-aldosterone system. Such approaches might slow decline in kidney function, but many patients progress to end-stage kidney failure despite optimal therapy. In recent clinical trials, new-generation glucose-lowering drug classes, the sodium-glucose co-transporter-2 inhibitors and agents that target the incretin pathway, have been shown to improve kidney outcomes in patients with type 2 diabetes. Other new approaches, which have been developed on the basis of an improved understanding of the mechanisms that contribute to kidney damage in the context of diabetes, include use of drugs that block endothelin receptors (eg, atrasentan) and non-steroidal mineralocorticoid receptors (eg, finerenone). In this Review, we provide an overview of recent clinical data relevant to these new therapeutic approaches for management of kidney disease in the context of type 2 diabetes.
引用
- Muskiet MHA, Wheeler DC, Heerspink HJL, et al. New pharmacological strategies for protecting kidney function in type 2 diabetes. Lancet Diabetes Endocrinol. 2018. PMID: 30579729. doi:10.1016/S2213-8587(18)30263-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。